Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC# 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged ≥1 to <31 Years Old with First Relapse
Protocol ID
AALL1821
Disease (Sub Disease)
Leukaemia (ALL)
Diagnosis Stage
Relapse
Sponsor
National Cancer Institute (NCI)
Links
Trial Status
Temporarily Closed
Study Type
Treatment
Phase
Phase 2
Age Eligibility
1 Year to 31 Years
International registry ID's
NCT04546399
| Study Title | Phase 2 Study of Blinatumomab (NSC# 765986 IND# 125462) in Combination with Nivolumab (NSC# 748726 IND# 125462) a Checkpoint Inhibitor of PD-1 in B-ALL Patients Aged ≥1 to <31 Years Old with First Relapse |
|---|---|
| Protocol ID | AALL1821 |
| Disease (Sub Disease) | Leukaemia (ALL) |
| Diagnosis Stage | Relapse |
| Sponsor | National Cancer Institute (NCI) |
| Links | https://clinicaltrials.gov/ct2/show/NCT04546399 |
| Trial Status | Temporarily Closed |
| Trial Open Date | 04/12/2020 |
| Study Type | Treatment |
| Phase | Phase 2 |
| Age Eligibility | 1 Year to 31 Years |
| International registry ID's | NCT04546399 |